Literature DB >> 19776552

China: public health genomics.

S Zheng1, M Song, L Wu, S Yang, J Shen, X Lu, J Du, W Wang.   

Abstract

China is a multicultural country that has arisen from its 56 ethnicities, with a diverse population of over 1.3 billion people and an imbalanced economic development. The health care system in China is tending to be overall funded through urban and rural health insurance plans. Although China has invested in the basic research of genome science, public health genomics-related programs and services in China started late. Prenatal screening is offered as part of routine clinical prenatal services and is free of charge in some economically advanced cities. Newborn screening programs are mandated throughout the country but vary between provinces and territories in terms of organization and diseases screened for; most screening tests are paid by out-of-pocket expenses. Genetic tests are encouraged while there are only one accredited state laboratory and few territorial laboratories in China. Further national genomics policies are needed in China in a range of genetic issues and infrastructure of public health genomics. Careful measurement is essential to understanding the nature and scale of the task ahead.

Entities:  

Mesh:

Year:  2009        PMID: 19776552     DOI: 10.1159/000240969

Source DB:  PubMed          Journal:  Public Health Genomics        ISSN: 1662-4246            Impact factor:   2.000


  6 in total

1.  Pharmacogenomics in Primary Care: A Crucial Entry Point for Global Personalized Medicine?

Authors:  Gillian Bartlett; Nathalie Zgheib; Aresha Manamperi; Wei Wang; Candan Hizel; Rabia Kahveci; Yasemin Yazan
Journal:  Curr Pharmacogenomics Person Med       Date:  2012

2.  Newborn screening for inborn errors of metabolism in mainland china: 30 years of experience.

Authors:  Xiao-Tong Shi; Juan Cai; Yuan-Yu Wang; Wen-Jun Tu; Wei-Peng Wang; Li-Ming Gong; Dao-Wen Wang; Yin-Tao Ye; Shao-Guang Fang; Peng-Wei Jing
Journal:  JIMD Rep       Date:  2012-01-31

3.  Analysis of efficacy and cost-effectiveness of high-dose arabinoside versus daunorubicin chemotherapy in older adult patients with acute myeloid leukemia by cytogenetic risk profile: retrospective review from China.

Authors:  Bin-Tao Huang; Yu Wang; Qing-Feng Du; Jun Yang; Jessica Yu; Qing-Chun Zeng; Na Xu; Jin-Fang Zhang; Lu-Lu Xu; Xu-Jing Luo; Yong-Qiang Wei; Xiao-Li Liu
Journal:  Int J Hematol       Date:  2011-03-10       Impact factor: 2.490

4.  Demographics, diagnosis and treatment of 256 patients with tetrahydrobiopterin deficiency in mainland China: results of a retrospective, multicentre study.

Authors:  Jun Ye; Yanling Yang; Weimin Yu; Hui Zou; Jianhui Jiang; Rulai Yang; Sunny Shang; Xuefan Gu
Journal:  J Inherit Metab Dis       Date:  2012-11-09       Impact factor: 4.982

5.  The availability and affordability of orphan drugs for rare diseases in China.

Authors:  Shiwei Gong; Yingxiao Wang; Xiaoyun Pan; Liang Zhang; Rui Huang; Xin Chen; Juanjuan Hu; Yi Xu; Si Jin
Journal:  Orphanet J Rare Dis       Date:  2016-02-27       Impact factor: 4.123

6.  Traditional Chinese medicine and new concepts of predictive, preventive and personalized medicine in diagnosis and treatment of suboptimal health.

Authors:  Wei Wang; Alyce Russell; Yuxiang Yan
Journal:  EPMA J       Date:  2014-02-13       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.